Dr. Mark R. Huber

Hematology Oncology | Hematology | Oncology
1325 S Cliff Ave, 
Sioux Falls, SD 
Accepting New Patients
Offers Telehealth
1325 S Cliff Ave, 
Sioux Falls, SD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Huber is a Hematologist Oncology specialist and a Hematologist in Sioux Falls, South Dakota. Dr. Huber is rated as an Experienced provider by MediFind in the treatment of BRCA Positive Breast Cancer. His top areas of expertise are Lung Cancer, Large-Cell Immunoblastic Lymphoma, Familial Wilms Tumor 2, WT1-Related Wilms Tumor Syndromes, and Bone Marrow Aspiration. Dr. Huber is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in SD
Hospital Affiliations
Avera St Mary's Hospital
Avera Marshall Regional Medical Ctr
Avera Queen Of Peace
Pipestone County Medical Center
Avera Mckennan Hospital & University Health Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

AVERA MCKENNAN
1325 S Cliff Ave, Sioux Falls, SD 57105
Other Locations
AVERA MARSHALL
300 S Bruce St, Marshall, MN 56258
AVERA MCKENNAN
400 22nd Ave, Brookings, SD 57006

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2026
Intervention Type: Other, Drug
Study Drugs: Enzalutamide, Rucaparib Camsylate, Leuprolide Acetate, Goserelin Acetate, Degarelix
Study Phase: Phase 3
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Terminated
Publish Date: January 24, 2025
Intervention Type: Biological, Drug
Study Drugs: HSPPC-96, Bevacizumab
Study Phase: Phase 2
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Enrollment Status: Unknown
Publish Date: May 24, 2022
Intervention Type: Drug, Procedure, Radiation
Study Drugs: mFOLFIRINOX, FOLFOX
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

2 Total Publications

Pembrolizumab Induced Acute Kidney Injury and Liver Injury in a Patient with Malignant Melanoma.
Pembrolizumab Induced Acute Kidney Injury and Liver Injury in a Patient with Malignant Melanoma.
Journal: South Dakota medicine : the journal of the South Dakota State Medical Association
Published: June 16, 2022
Similar Doctors
Experienced in BRCA Positive Breast Cancer
Dr. Jamie E. Mckenzie
Hematology Oncology | Hematology | Oncology
Experienced in BRCA Positive Breast Cancer
Dr. Jamie E. Mckenzie
Hematology Oncology | Hematology | Oncology

Sanford Health Network

20 S Plum St, 
Vermillion, SD 
 (53.2 miles away)
605-624-9111
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jamie Mckenzie is a Hematologist Oncology specialist and a Hematologist in Vermillion, South Dakota. Dr. Mckenzie is rated as an Advanced provider by MediFind in the treatment of BRCA Positive Breast Cancer. Her top areas of expertise are HER-2 Positive Breast Cancer, Angiosarcoma, Inflammatory Breast Cancer, and Paget Disease of the Breast. Dr. Mckenzie is currently accepting new patients.

Experienced in BRCA Positive Breast Cancer
Dr. Jason M. Jones
Hematology Oncology | Hematology | Oncology
Experienced in BRCA Positive Breast Cancer
Dr. Jason M. Jones
Hematology Oncology | Hematology | Oncology

Avera Mckennan

1000 E 23rd St, Suite 230, 
Sioux Falls, SD 
 (0.2 miles away)
605-322-6900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jason Jones is a Hematologist Oncology specialist and a Hematologist in Sioux Falls, South Dakota. Dr. Jones is rated as an Advanced provider by MediFind in the treatment of BRCA Positive Breast Cancer. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma. Dr. Jones is currently accepting new patients.

Keely M. Hack
Experienced in BRCA Positive Breast Cancer
Dr. Keely M. Hack
Hematology Oncology | Hematology | Oncology
Experienced in BRCA Positive Breast Cancer
Dr. Keely M. Hack
Hematology Oncology | Hematology | Oncology

Sanford Medical Center

1301 W 18th St, 
Sioux Falls, SD 
 (1.6 miles away)
605-312-2200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Keely Hack is a Hematologist Oncology specialist and a Hematologist in Sioux Falls, South Dakota. Dr. Hack is rated as a Distinguished provider by MediFind in the treatment of BRCA Positive Breast Cancer. Her top areas of expertise are Angiosarcoma, Inflammatory Breast Cancer, Paget Disease of the Breast, Bone Marrow Aspiration, and Gastrostomy. Dr. Hack is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Huber's expertise for a condition
ConditionClose
    View All 12 Distinguished Conditions
    View All 65 Advanced Conditions
    View All 143 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile